Kidney disease: Latest News, Top Stories & Analysis

Mineralys Reports Kidney Disease Data Ahead of FDA Decision

June 4, 2026June 3, 2026 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) reported new Phase 3 data suggesting its experimental hypertension treatment lorundrostat may provide benefits for patients with chronic kidney disease, a finding that …

Regional

Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial

February 5, 2025February 4, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The study is evaluating the efficacy and safety of lorundrostat, …